New to The Street Announces Episode 576, Four Business Guest Interviews, Airs on Bloomberg TV as Sponsored Programming, Tonight, Thursday, June 6, 2024, at 9:30 PM PT

FMW Media Works Corp
FMW Media Works Corp

In This Article:

New to The Street TV Announces Episode 576, Five Business Guest Interviews, Airs on Bloomberg TV as Sponsored Programming, Tonight, Thursday, June 6, 2024, at 9:30 PM PT

Episode 576: 1). Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ($ACXP) 2). R La Rosa Holdings Corps. (NASDAQ: LRHC) ($LRHC) 3). Greene Concepts, Inc. (OTCMarkets: INKW)($INKW) 4). Sekur Private Data, Ltd. (OTCQB: SWISF) (CSE: SKUR) (FRA: GDT0) ($SWISF) (Sekur®) - www.newtothestreet.com
Episode 576: 1). Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ($ACXP) 2). R La Rosa Holdings Corps. (NASDAQ: LRHC) ($LRHC) 3). Greene Concepts, Inc. (OTCMarkets: INKW)($INKW) 4). Sekur Private Data, Ltd. (OTCQB: SWISF) (CSE: SKUR) (FRA: GDT0) ($SWISF) (Sekur?) - www.newtothestreet.com

NEW YORK, June 06, 2024 (GLOBE NEWSWIRE) -- FMW Media's New to The Street announces the broadcasting of its national business TV show airing on Bloomberg TV as sponsored programming tonight, Thursday, June 6, 2024, at 9:30 PM PT.

New to The Street's TV episode 576 will air the following four (4) business interviews:

1). Biopharmaceutical - Acurx Pharmaceuticals, Inc.'s (NASDAQ: ACXP) ($ACXP) interview with David Luci, President/CEO.

2). Real Estate - La Rosa Holdings Corp's. (NASDAQ: LRHC) ($LRHC) interviews with Joe La Rosa, Founder and CEO, and José Couverte, Team Leader & Talent Acquisition Advisor.

3). "Game Changers" segment interview with Greene Concepts, Inc.'s (OTCMarkets: INKW) ($INKW) Lenny Greene, CEO and President.

4). "Sekur Privacy & Sekur Security – The Weekly Hack” segment with internet privacy expert Mr. Alain Ghiai, CEO, Sekur Private Data, Ltd. (OTCQB: SWISF) (CSE: SKUR) (FRA: GDT0) ($SWISF) (Sekur?).

Episode 576

New to The Street's TV Host Jane King from the Nasdaq MarketSite Studio talks with David Luci, the President/CEO of Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ($ACXP) ("Company"), a late-stage biopharmaceutical Company. ACXP is developing a new class of small molecular antibiotics for life-threatening bacterial infections. With the successful completion of Phase 2 clinical trials on the Ibezapolstat drug, a treatment for patients with Clostridioides difficile Infections (CDI), management met with the FDA to map out a pathway for a full FDA drug approval. David tells viewers that the meeting was successful and that the FDA and ACXP agreed on a Phase 3 clinical trial protocol. Once fully approved, the Company will have the opportunity to pursue worldwide partnerships and revenue-streaming agreements. Over the next couple of years, David and the ACXP team expect a successful Phase 3 trial with full FDA approval. ACXP believes Ibezapolstat could be a market worth over $1B. As such, its shareholder base and stock prices could greatly benefit once the regulatory agencies in the USA and internationally approve the drug. Clinical data to date on completed trials have shown that the Ibezapolstat drug effectively treats CDI with no reinfections. The on-screen QR code is available during the show; download or visit Acurx Pharmaceuticals, Inc. - https://www.acurxpharma.com/.